These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

504 related articles for article (PubMed ID: 25449231)

  • 1. Immunizations with hepatitis B viral antigens and a TLR7/8 agonist adjuvant induce antigen-specific immune responses in HBV-transgenic mice.
    Wang Y; Chen K; Wu Z; Liu Y; Liu S; Zou Z; Chen SH; Qu C
    Int J Infect Dis; 2014 Dec; 29():31-6. PubMed ID: 25449231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL-12-based vaccination therapy reverses liver-induced systemic tolerance in a mouse model of hepatitis B virus carrier.
    Zeng Z; Kong X; Li F; Wei H; Sun R; Tian Z
    J Immunol; 2013 Oct; 191(8):4184-93. PubMed ID: 24048897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis B surface antigen (HBsAg) and core antigen (HBcAg) combine CpG oligodeoxynucletides as a novel therapeutic vaccine for chronic hepatitis B infection.
    Li J; Ge J; Ren S; Zhou T; Sun Y; Sun H; Gu Y; Huang H; Xu Z; Chen X; Xu X; Zhuang X; Song C; Jia F; Xu A; Yin X; Du SX
    Vaccine; 2015 Aug; 33(35):4247-54. PubMed ID: 25858855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overcoming HBV immune tolerance to eliminate HBsAg-positive hepatocytes via pre-administration of GM-CSF as a novel adjuvant for a hepatitis B vaccine in HBV transgenic mice.
    Wang X; Dong A; Xiao J; Zhou X; Mi H; Xu H; Zhang J; Wang B
    Cell Mol Immunol; 2016 Nov; 13(6):850-861. PubMed ID: 26166767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TLR8 agonists stimulate newly recruited monocyte-derived cells into potent APCs that enhance HBsAg immunogenicity.
    Du J; Wu Z; Ren S; Wei Y; Gao M; Randolph GJ; Qu C
    Vaccine; 2010 Aug; 28(38):6273-81. PubMed ID: 20637759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lentiviral vector encoding ubiquitinated hepatitis B core antigen induces potent cellular immune responses and therapeutic immunity in HBV transgenic mice.
    Dai S; Zhuo M; Song L; Chen X; Yu Y; Zang G; Tang Z
    Immunobiology; 2016 Jul; 221(7):813-21. PubMed ID: 26874581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heat shock protein gp96 enhances humoral and T cell responses, decreases Treg frequency and potentiates the anti-HBV activity in BALB/c and transgenic mice.
    Wang S; Qiu L; Liu G; Li Y; Zhang X; Jin W; Gao GF; Kong X; Meng S
    Vaccine; 2011 Aug; 29(37):6342-51. PubMed ID: 21600951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus.
    Akbar SM; Chen S; Al-Mahtab M; Abe M; Hiasa Y; Onji M
    Antiviral Res; 2012 Oct; 96(1):59-64. PubMed ID: 22884884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice.
    Buchmann P; Dembek C; Kuklick L; Jäger C; Tedjokusumo R; von Freyend MJ; Drebber U; Janowicz Z; Melber K; Protzer U
    Vaccine; 2013 Feb; 31(8):1197-203. PubMed ID: 23306359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inducing oral immune regulation of hepatitis B virus envelope proteins suppresses the growth of hepatocellular carcinoma in mice.
    Gotsman I; Alper R; Klein A; Rabbani E; Engelhardt D; Ilan Y
    Cancer; 2002 Jan; 94(2):406-14. PubMed ID: 11900226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overcoming tolerance in hepatitis B virus transgenic mice: a possible involvement of regulatory T cells.
    Roh S; Kim K
    Microbiol Immunol; 2003; 47(6):453-60. PubMed ID: 12906106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nasal route favors the induction of CD4
    Bourgine M; Crabe S; Lobaina Y; Guillen G; Aguilar JC; Michel ML
    Antiviral Res; 2018 May; 153():23-32. PubMed ID: 29510155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel TLR7 agonist as adjuvant to stimulate high quality HBsAg-specific immune responses in an HBV mouse model.
    Hu Y; Tang L; Zhu Z; Meng H; Chen T; Zhao S; Jin Z; Wang Z; Jin G
    J Transl Med; 2020 Mar; 18(1):112. PubMed ID: 32131853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of immune tolerance toward tumor-associated-antigens enables growth of human hepatoma in mice.
    Gotsman I; Israeli D; Alper R; Rabbani E; Engelhardt D; Ilan Y
    Int J Cancer; 2002 Jan; 97(1):52-7. PubMed ID: 11774243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High persistence rate of hepatitis B virus in a hydrodynamic injection-based transfection model in C3H/HeN mice.
    Peng XH; Ren XN; Chen LX; Shi BS; Xu CH; Fang Z; Liu X; Chen JL; Zhang XN; Hu YW; Zhou XH
    World J Gastroenterol; 2015 Mar; 21(12):3527-36. PubMed ID: 25834317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breaking tolerance leads to autoantibody production but not autoimmune liver disease in hepatitis B virus envelope transgenic mice.
    Wirth S; Guidotti LG; Ando K; Schlicht HJ; Chisari FV
    J Immunol; 1995 Mar; 154(5):2504-15. PubMed ID: 7868916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenovirus Vector Harboring the HBcAg and Tripeptidyl Peptidase II Genes Induces Potent Cellular Immune Responses In Vivo.
    Tan Q; Ma S; Hu J; Chen X; Yu Y; Tang Z; Zang G
    Cell Physiol Biochem; 2017; 41(2):423-438. PubMed ID: 28214886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A mouse model with age-dependent immune response and immune-tolerance for HBV infection.
    Yi X; Yuan Y; Li N; Yi L; Wang C; Qi Y; Gong L; Liu G; Kong X
    Vaccine; 2018 Feb; 36(6):794-801. PubMed ID: 29306503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of CD4 T cells during prime immunization determines the success of a therapeutic hepatitis B vaccine in HBV-carrier mouse models.
    Su J; Brunner L; Ates Oz E; Sacherl J; Frank G; Kerth HA; Thiele F; Wiegand M; Mogler C; Aguilar JC; Knolle PA; Collin N; Kosinska AD; Protzer U
    J Hepatol; 2023 Apr; 78(4):717-730. PubMed ID: 36634821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JNJ-64794964 (AL-034/TQ-A3334), a TLR7 agonist, induces sustained anti-HBV activity in AAV/HBV mice via non-cytolytic mechanisms.
    Herschke F; Li C; Zhu R; Han Q; Wu Q; Lu Q; Barale-Thomas E; De Jonghe S; Lin TI; De Creus A
    Antiviral Res; 2021 Dec; 196():105196. PubMed ID: 34718044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.